Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute to neuroprotection in a traumatic brain injury

Alzheimer's Research and Therapy

Volumn 5, Issue 5, 2013, Pages

  Kitagishi, Yasuko ^a   Matsuda, Satoru ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CURCUMIN; FATTY ACID BINDING PROTEIN 4; FISH OIL; GAMMA LINOLENIC ACID; GENISTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR 1; ICOSAPENTAENOIC ACID; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RESVERATROL; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; RETINOL DERIVATIVE;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIET; DIETARY INTAKE; ENZYME ACTIVITY; HUMAN; LIPID METABOLISM; NERVE CELL; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY;

EID: 84887867561     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt208     Document Type: Review

References (70)

1. Animal models of traumatic brain injury. Xiong Y, Mahmood A, Chopp M, Nat Rev Neurosci 2013 14 128 142 23329160
2. Traumatic brain injury: networks and neuropathology. Levin H, Smith D, Lancet Neurol 2013 12 15 16 10.1016/S1474-4422(12)70300-9 23237894
3. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Cheng G, Kong RH, Zhang LM, Zhang JN, Br J Pharmacol 2012 16 699 719 23003569
4. Attenuation of brain edema and spatial learning deficits by the inhibition of NADPH oxidase activity using apocynin following diffuse traumatic brain injury in rats. Song SX, Gao JL, Wang KJ, Li R, Tian YX, Wei JQ, Cui JZ, Mol Med Rep 2012 Oct 24 [Epub ahead of print] 23128834
5. Pathway analysis reveals common pro-survival mechanisms of metyrapone and carbenoxolone after traumatic brain injury. Hellmich HL, Rojo DR, Micci MA, Sell SL, Boone DR, Crookshanks JM, DeWitt DS, Masel BE, Prough DS, PLoS One 2013 8 53230 10.1371/journal.pone.0053230 23326402
6. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. Al-Gubory KH, Fowler PA, Garrel C, Int J Biochem Cell Biol 2010 42 1634 1650 10.1016/j.biocel.2010.06.001 20601089
7. Redox control of the survival of healthy and diseased cells. Zhang Y, Du Y, Le W, Wang K, Kieffer N, Zhang J, Antioxid Redox Signal 2011 15 2867 2908 10.1089/ars.2010.3685 21457107
8. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. Scatena R, Adv Exp Med Biol 2012 942 287 308 10.1007/978-94-007-2869-1-13 22399428
9. Drosophila simulans as a novel model for studying mitochondrial metabolism and aging. Ballard JW, Exp Gerontol 2005 40 763 773 10.1016/j.exger.2005.07.014 16169180 (Pubitemid 41416539)
10. Membrane trafficking of NADPH oxidase p47(phox) in paraventricular hypothalamic neurons parallels local free radical production in angiotensin II slow-pressor hypertension. Coleman CG, Wang G, Faraco G, Marques Lopes J, Waters EM, Milner TA, Iadecola C, Pickel VM, J Neurosci 2013 33 4308 4316 10.1523/JNEUROSCI.3061-12.2013 23467347
11. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Li ZY, Yang Y, Ming M, Liu B, Biochem Biophys Res Commun 2011 414 5 8 10.1016/j.bbrc.2011.09.046 21951851
12. Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. Gillette-Guyonnet S, Secher M, Vellas B, Br J Clin Pharmacol 2013 75 738 755 23384081
13. Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation. Choi BY, Jang BG, Kim JH, Lee BE, Sohn M, Song HK, Suh SW, Brain Res 2012 1481 49 58 22975130
14. The p53 tumor suppressor protein regulates hematopoietic stem cell fate. Asai T, Liu Y, Bae N, Nimer SD, J Cell Physiol 2011 226 2215 2221 10.1002/jcp.22561 21660944
15. The molecular mechanism underlying morphine-induced Akt activation: roles of protein phosphatases and reactive oxygen species. Xu J, Tian W, Ma X, Guo J, Shi Q, Jin Y, Xi J, Xu Z, Cell Biochem Biophys 2011 61 303 311 10.1007/s12013-011-9213-5 21626435
16. Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4,5-bisphosphate depletion. Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, Dorn GW 2nd, Woodcock EA, Brown JH, J Biol Chem 2003 278 40343 40351 10.1074/jbc.M305964200 12900409 (Pubitemid 37248603)
17. Homeostatic regulation of AMPA receptor expression at single hippocampal synapses. Hou Q, Zhang D, Jarzylo L, Huganir RL, Man HY, Proc Natl Acad Sci U S A 2008 105 775 780 10.1073/pnas.0706447105 18174334 (Pubitemid 351171784)
18. Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease. Damjanac M, Rioux Bilan A, Paccalin M, Pontcharraud R, Fauconneau B, Hugon J, Page G, Neurobiol Dis 2008 29 354 367 10.1016/j.nbd.2007.09.008 18023354
19. Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease. De Gasperi R, Sosa MA, Dracheva S, Elder GA, Mol Neurodegener 2010 5 38 10.1186/1750-1326-5-38 20863403
20. GSK3beta activity modifies the localization and function of presenilin 1. Uemura K, Kuzuya A, Shimozono Y, Aoyagi N, Ando K, Shimohama S, Kinoshita A, J Biol Chem 2007 282 15823 15832 10.1074/jbc.M610708200 17389597 (Pubitemid 47093307)
21. Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Ryder J, Su Y, Ni B, Cell Signal 2004 16 187 200 10.1016/j.cellsig.2003.07.004 14636889 (Pubitemid 37431168)
22. Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway. Cheng B, Martinez AA, Morado J, Scofield V, Roberts JL, Maffi SK, Neurochem Int 2013 62 31 42 10.1016/j.neuint.2012.10.014 23142153
23. PTEN in brain tumors. Haas-Kogan D, Stokoe D, Expert Rev Neurother 2008 8 599 610 10.1586/14737175.8.4.599 18416662 (Pubitemid 351551012)
24. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Gupta A, Dey CS, Mol Biol Cell 2012 23 3882 3898 10.1091/mbc.E12-05-0337 22875989
25. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR, Mol Cell Biol 2000 20 8969 8982 10.1128/MCB.20.23.8969-8982.2000 11073996 (Pubitemid 32245927)
26. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Mulholland DJ, Dedhar S, Wu H, Nelson CC, Oncogene 2006 25 329 337 10.1038/sj.onc.1209020 16421604 (Pubitemid 43117618)
27. Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. Fournier MV, Fata JE, Martin KJ, Yaswen P, Bissell MJ, Cancer Res 2009 69 4545 4552 10.1158/0008-5472.CAN-08-1694 19417140
28. Presenilins regulate the cellular level of the tumor suppressor PTEN. Zhang H, Liu R, Wang R, Hong S, Xu H, Zhang YW, Neurobiol Aging 2008 29 653 660 10.1016/j.neurobiolaging.2006.11.020 17222949 (Pubitemid 351400825)
29. Molecular insights into Parkinson's disease. Rochet JC, Hay BA, Guo M, Prog Mol Biol Transl Sci 2012 107 125 188 22482450
30. Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal peroxisome proliferator activated receptors (PPARα and PPARγ) gene expression in rats. Hajjar T, Meng GY, Rajion MA, Vidyadaran S, Othman F, Farjam AS, Li TA, Ebrahimi M, BMC Neurosci 2012 13 109 10.1186/1471-2202-13-109 22989138
31. Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Yuan X, Zhang Z, Gong K, Zhao P, Qin J, Liu N, Biol Pharm Bull 2011 34 618 623 10.1248/bpb.34.618 21532147
32. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F, Nature 2008 456 350 356 19043829
33. The expression of nuclear retinoid receptors in human implantation. Tarrade A, Rochette-Egly C, Guibourdenche J, Evain-Brion D, Placenta 2000 21 703 710 10.1053/plac.2000.0568 10985974
34. International Union of Pharmacology. LXI. Peroxisome proliferator- activated receptors. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W, Pharmacol Rev 2006 58 726 741 10.1124/pr.58.4.5 17132851 (Pubitemid 44833742)
35. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT, J Neurosci 2012 32 17321 17331 10.1523/JNEUROSCI.1569-12. 2012 23197723
36. Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways. Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Wood TG, Dineley KT, J Neurosci 2012 32 16725 16735a 10.1523/JNEUROSCI.2153-12.2012 23175826
37. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, Science 2012 335 1503 1506 10.1126/science.1217697 22323736
38. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J, Magnuson MA, Wu H, Mol Cell Biol 2006 26 2772 2781 10.1128/MCB.26.7.2772-2781.2006 16537919
39. Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V, Mol Cell Biochem 2010 337 299 305 10.1007/s11010-009- 0312-1 19911253
40. Induction of gene encoding FABP4 in Pten-null keratinocytes. Tsuda M, Inoue-Narita T, Suzuki A, Itami S, Blumenberg M, Manabe M, FEBS Lett 2009 583 1319 1322 10.1016/j.febslet.2009.03.030 19303874
41. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H, Proc Natl Acad Sci U S A 2004 101 2082 2087 10.1073/pnas.0308617100 14769918 (Pubitemid 38229018)
42. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. Lecka-Czernik B, IDrugs 2010 13 793 801 21046527
43. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Knobbe CB, Lapin V, Suzuki A, Mak TW, Oncogene 2008 27 5398 5415 10.1038/onc.2008.238 18794876
44. Ethanol extract of rosemary repressed PTEN expression in K562 culture cells. Yoshida H, Okumura N, Kitagishi Y, Nishimura Y, Matsuda S, Int J Appl Biol Pharm Technol 2011 2 316 322
45. Inhibition of PTEN by peroxynitrite activates the phosphoinositide-3- kinase/Akt neuroprotective signaling pathway. Delgado-Esteban M, Martin-Zanca D, Andres-Martin L, Almeida A, Bolaños JP, J Neurochem 2007 102 194 205 10.1111/j.1471-4159.2007.04450.x 17302912 (Pubitemid 46906253)
46. Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating Akt survival pathway. Fuentealba RA, Liu Q, Kanekiyo T, Zhang J, Bu G, J Biol Chem 2009 284 34045 34053 10.1074/jbc.M109.021030 19815552
47. Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. Chen LM, Xiong YS, Kong FL, Qu M, Wang Q, Chen XQ, Wang JZ, Zhu LQ, J Neurochem 2012 120 157 164 10.1111/j.1471-4159.2011.07275.x 21496024
48. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. Zhang C, Browne A, Child D, Tanzi RE, J Biol Chem 2010 285 28472 28480 10.1074/jbc.M110.133520 20622013
49. A pyrazole curcumin derivative restores membrane homeostasis disrupted after brain trauma. Sharma S, Ying Z, Gomez-Pinilla F, Exp Neurol 2010 226 191 199 10.1016/j.expneurol.2010.08.027 20816821
50. Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4? Laird MD, Sukumari-Ramesh S, Swift AE, Meiler SE, Vender JR, Dhandapani KM, J Neurochem 2010 113 637 648 10.1111/j.1471-4159.2010.06630.x 20132469
51. HDAC1 expression and effect of curcumin on proliferation of Raji cells. Wu Q, Chen Y, Li X, J Huazhong Univ Sci Technolog Med Sci 2006 26 199 201 10.1007/BF02895815 16850746
52. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Wang R, Li YH, Xu Y, Li YB, Wu HL, Guo H, Zhang JZ, Zhang JJ, Pan XY, Li XJ, Prog Neuropsychopharmacol Biol Psychiatry 2010 34 147 153 10.1016/j.pnpbp.2009.10.016 19879308
53. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM, J Neurosci 2009 29 9078 9089 10.1523/JNEUROSCI.1071-09.2009 19605645
54. Turmeric and curcumin suppress presenilin 1 protein expression in Jurkat cells. Yoshida H, Okumura N, Nishimura Y, Kitagishi Y, Matsuda S, Exp Ther Med 2011 2 629 632 22977552
55. Lesion-induced hippocampal plasticity in transgenic Alzheimer's disease mouse models: influences of age, genotype, and estrogen. Kadish I, van Groen T, J Alzheimers Dis 2009 18 429 445 19584452
56. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway. Liang C, Li H, Shen C, Lai J, Shi Z, Liu B, Tao HM, Anticancer Agents Med Chem 2012 12 554 563 10.2174/187152012800617867 22263786
57. Curcuminoids and resveratrol as anti-Alzheimer agents. Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY, Taiwan J Obstet Gynecol 2012 51 515 525 10.1016/j.tjog.2012.09.005 23276553
58. Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL, PLoS One 2011 6 29102 10.1371/journal.pone.0029102 22220203
59. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Li F, Gong Q, Dong H, Shi J, Curr Pharm Des 2012 18 27 33 10.2174/138161212798919075 22211686
60. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE, Neurochem Int 2009 54 111 118 10.1016/j.neuint.2008.10. 008 19041676
61. Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P, J Neurochem 2012 120 461 472 10.1111/j.1471-4159.2011.07594.x 22118570
62. Fibrates: therapeutic potential for diabetic nephropathy? Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis DP, Eur J Intern Med 2012 23 309 316 10.1016/j.ejim.2011.12.007 22560376
63. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ, Am J Med 2012 125 126 133 10.1016/j.amjmed. 2011.08.025 22269613
64. Hypolipidemic activity in Sprague-Dawley rats and constituents of a novel natural vegetable oil from Cornus wilsoniana fruits. Fu J, Zhang XW, Liu K, Li QS, Zhang LR, Yang XH, Zhang ZM, Li CZ, Luo Y, He ZX, Zhu HL, Food Sci 2012 77 160 H169 10.1111/j.1750-3841.2012.02786.x 22747885
65. Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. Donohue MC, Aisen PS, J Nutr Health Aging 2012 16 360 364 10.1007/s12603-012-0047-7 22499459
66. The role of nutrition and diet in Alzheimer disease: a systematic review. Shah R, J Am Med Dir Assoc 2013 14 398 402 10.1016/j.jamda.2013.01.014 23419980
67. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Swanson D, Block R, Mousa SA, Adv Nutr 2012 3 1 7 10.3945/an.111.000893 22332096
68. Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. Calon F, Curr Alzheimer Res 2011 8 470 478 10.2174/156720511796391881 21605051
69. Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist. Goncalves MB, Clarke E, Hobbs C, Malmqvist T, Deacon R, Jack J, Corcoran JP, Eur J Neurosci 2013 37 1182 1192 10.1111/ejn.12142 23379615
70. Retinoids for treatment of Alzheimer's disease. Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G, Biofactors 2012 38 84 89 10.1002/biof.196 22419567